AR062357A1 - Derivados de fenilo, piridina y quinolina, composiciones farmaceuticas y su utilizacion como medicamentos - Google Patents
Derivados de fenilo, piridina y quinolina, composiciones farmaceuticas y su utilizacion como medicamentosInfo
- Publication number
- AR062357A1 AR062357A1 ARP070103583A ARP070103583A AR062357A1 AR 062357 A1 AR062357 A1 AR 062357A1 AR P070103583 A ARP070103583 A AR P070103583A AR P070103583 A ARP070103583 A AR P070103583A AR 062357 A1 AR062357 A1 AR 062357A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- halogen
- alkoxy
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 34
- 229910052739 hydrogen Inorganic materials 0.000 abstract 21
- 239000001257 hydrogen Substances 0.000 abstract 21
- 125000003545 alkoxy group Chemical group 0.000 abstract 17
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical class 0.000 abstract 12
- 150000002431 hydrogen Chemical group 0.000 abstract 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 9
- -1 amino, pyrrolyl Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000005159 cyanoalkoxy group Chemical group 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se refiere además a composiciones farmacéuticas que contienen tales compuestos, a un proceso para su obtencion y a su utilizacion para el tratamiento y/o prevencion de enfermedades, que están asociadas con la modulacion de los receptores de la SST del subtipo 5. Reivindicacion 1: Compuestos de la formula (1) en la que A es -O- o -NH-; R1 se elige entre el grupo formado por hidrogeno, alcoxi C1-7 y halogeno; R2 se elige entre el grupo formado por alquilo C2-7, alquenilo C2-7, halogeno-alquilo C1-7, (alcoxi C1-7)-alquilo C1-7 y bencilo; R3 se elige entre el grupo formado por hidrogeno, alquilo C1-7, hidroxi, alcoxi C1-7, alqueniloxi C2-7, hidroxi-alcoxi C1-7, (alcoxi C1-7)-alcoxi C1-7, -O-cicloalquilo C3-7, halogeno, halogeno-alquilo C1- 7, halogeno-alcoxi C1-7, -C(O)OR6, en el que R6 es alquilo C1-7, amino, pirrolilo, fenilo sin sustituir o fenilo sustituido de una a tres veces por restos elegidos con independencia entre alquilo C1-7, halogeno y alcoxi C1-7; R4 se elige entre el grupo formado por hidrogeno, hidroxi, alcoxi C1-7, amino, nitro, hidroxi-alcoxi C1-7, (alcoxi C1-7)-alcoxi C1-7 y -O-bencilo; o R3 y R4 están unidos entre sí para formar un anillo junto con los átomos de carbono a los que están unidos y R3 y R4 son, juntos, un resto -O-C(CH3)2-CH=CH-; R5 se elige entre el grupo formado por hidrogeno, halogeno y alcoxi C1-7; G se elige entre los restos del grupo de formulas (2), en los que R7 y R11 son hidrogeno; R8 y R10 con independencia entre sí son hidrogeno o -NH-C(O)- R25, en el que R25 es alquilo C1-7; R9 se elige entre el grupo formado por hidrogeno, alquilo C1-7, halogeno, halogeno-alquilo C1-7, ciano, -C(O)OR26, en el que R26 es hidrogeno o alquilo C1-7, -(CH2)m-S(O)2-NH-R27, en el que m es el numero 0 o 1 y R27 se elige entre alquilo C1-7, heteroarilo sin sustituir y heteroarilo sustituido por alquilo C1-7; y -NH-S(O)2-R28, en el que R28 es alquilo C1-7; o R8 y R9 están unidos entre sí para formar un anillo junto con los átomos de carbono a los que están unidos y R8 y R9 son, juntos, -CH2-S(O)2-CH2-; R12 se elige entre el grupo formado por hidrogeno, alquilo C1-7, halogeno y amino; R13 se elige entre el grupo formado por hidrogeno, alquilo C1-7, halogeno, halogeno-alquilo C1- 7, ciano, nitro, fenilo, tetrazolilo, benzoimidazolilo, -COOR29, en el que R29 es hidrogeno o alquilo C1-7, hidroxi-alcoxi C1-7, ciano-alcoxi C1-7, -CONHR30, en el que R30 se elige entre el grupo formado por hidrogeno, alquilo C1-7, cicloalquilo C3- 7, hidroxi-alquilo C1-7, (alcoxi C1-7)-alquilo C1-7, halogeno-alquilo C1-7, carboxi-alquilo C1-7, -(CH2)n-NH-C(O)-R31, en el que n es el numero 1 o 2 y R31 es alquilo C1-7, -S(O)2R33, en el que R33 es alquilo C1-7, -O-S(O)2-R34, en el que R34 es alquilo C1-7 y -CO-heterociclilo, dicho heterociclilo es un anillo elegido entre pirrolidinilo, piperidinilo, piperazinilo y morfolinilo, dicho anillo está sin sustituir o sustituido por un resto elegido entre hidroxi, carboxi, carbamoílo y alcanoílo C1-7; R14 se elige entre el grupo formado por hidrogeno, alquilo C1-7, alcoxi C1-7, (alcoxi C1-7)-alquilo C1-7, ciano, carbamoílo, -COOR35, en el que R35 es hidrogeno o alquilo C1-7, halogeno y halogeno-alquilo C1-7; R15 se elige entre el grupo formado por hidrogeno, ciano, halogeno y halogeno-alquilo C1-7; R16 y R18 son hidrogeno; R17 es carbamoílo o -COOR32, en el que R32 es hidrogeno o alquilo C1-7; R19 es hidrogeno o halogeno; R20 se elige entre el grupo formado por hidrogeno, alquilo C1-7, alcoxi C1-7, (alcoxi C1-7)-alquilo C1-7 y halogeno; R21, R22 y R23 con independencia entre sí son hidrogeno o halogeno; R24 es hidrogeno o alquilo C1-7; y las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06118923 | 2006-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062357A1 true AR062357A1 (es) | 2008-11-05 |
Family
ID=38779568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103583A AR062357A1 (es) | 2006-08-15 | 2007-08-13 | Derivados de fenilo, piridina y quinolina, composiciones farmaceuticas y su utilizacion como medicamentos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7754744B2 (es) |
| EP (1) | EP2054385A2 (es) |
| JP (1) | JP2010500391A (es) |
| KR (1) | KR101117931B1 (es) |
| CN (1) | CN101506165B (es) |
| AR (1) | AR062357A1 (es) |
| AU (1) | AU2007286344A1 (es) |
| BR (1) | BRPI0715967A2 (es) |
| CA (1) | CA2658960A1 (es) |
| CL (1) | CL2007002347A1 (es) |
| IL (1) | IL196599A0 (es) |
| MX (1) | MX2009001498A (es) |
| PE (1) | PE20080543A1 (es) |
| TW (1) | TW200817362A (es) |
| WO (1) | WO2008019967A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| KR101506156B1 (ko) | 2007-04-23 | 2015-03-26 | 얀센 파마슈티카 엔.브이. | 속해리성 도파민 2 수용체 길항제로서의 티아(디아)졸 |
| RU2480462C2 (ru) * | 2007-04-23 | 2013-04-27 | Янссен Фармацевтика Н.В. | Производные пиридина, используемые в качестве быстро диссоциирующихся антагонистов допаминовых рецепторов 2 |
| ES2398625T3 (es) | 2008-07-03 | 2013-03-20 | Janssen Pharmaceutica N.V. | 6-(1-Piperazinil)-piritazinas sustituidas como antagonistas de receptores 5-HT6 |
| HUE033768T2 (en) | 2008-07-31 | 2017-12-28 | Janssen Pharmaceutica Nv | Piperazin-1-yl-trifluoromethyl-substituted pyridines as rapidly dissociating dopamine-2 receptor antagonists |
| BRPI0918045A2 (pt) * | 2008-09-18 | 2015-12-01 | Astellas Pharma Inc | compostos de carboxamida heterocíclicos |
| WO2012024183A1 (en) | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2015046482A1 (ja) | 2013-09-30 | 2015-04-02 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| JO3442B1 (ar) * | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
| DK3063139T3 (en) * | 2013-10-29 | 2019-03-11 | Takeda Pharmaceuticals Co | HETEROCYCLIC COMPOUND |
| TW201712012A (zh) | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物 |
| US10246453B2 (en) | 2016-05-20 | 2019-04-02 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| CA3042004A1 (en) | 2016-12-09 | 2018-06-14 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| MX2019010949A (es) | 2017-03-16 | 2019-10-24 | Crinetics Pharmaceuticals Inc | Moduladores de somatostatina y usos de los mismos. |
| WO2019157458A1 (en) | 2018-02-12 | 2019-08-15 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| EP3807281A1 (en) | 2018-06-13 | 2021-04-21 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| EP3844158A1 (en) | 2018-08-31 | 2021-07-07 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| WO2020061046A1 (en) | 2018-09-18 | 2020-03-26 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| JP7080405B2 (ja) * | 2018-12-03 | 2022-06-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | バニン阻害剤としての複素芳香族化合物 |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| US20230041621A1 (en) * | 2019-12-03 | 2023-02-09 | Kallyope, Inc. | Sstr5 antagonists |
| JP7553547B2 (ja) | 2020-03-31 | 2024-09-18 | エヌ・イーケムキャット株式会社 | 芳香族化合物の製造方法 |
| CA3207378A1 (en) | 2021-02-17 | 2022-08-25 | Yuxin Zhao | Crystalline forms of a somatostatin modulator |
| CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
| WO2024129614A1 (en) | 2022-12-13 | 2024-06-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| US6921821B2 (en) * | 2002-06-12 | 2005-07-26 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
| AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
-
2007
- 2007-08-06 MX MX2009001498A patent/MX2009001498A/es active IP Right Grant
- 2007-08-06 US US11/834,184 patent/US7754744B2/en not_active Expired - Fee Related
- 2007-08-06 CA CA002658960A patent/CA2658960A1/en not_active Abandoned
- 2007-08-06 KR KR1020097002961A patent/KR101117931B1/ko not_active IP Right Cessation
- 2007-08-06 JP JP2009524168A patent/JP2010500391A/ja active Pending
- 2007-08-06 AU AU2007286344A patent/AU2007286344A1/en not_active Abandoned
- 2007-08-06 BR BRPI0715967-6A patent/BRPI0715967A2/pt not_active IP Right Cessation
- 2007-08-06 EP EP07788237A patent/EP2054385A2/en not_active Withdrawn
- 2007-08-06 WO PCT/EP2007/058114 patent/WO2008019967A2/en active Application Filing
- 2007-08-06 CN CN2007800303854A patent/CN101506165B/zh not_active Expired - Fee Related
- 2007-08-13 CL CL200702347A patent/CL2007002347A1/es unknown
- 2007-08-13 AR ARP070103583A patent/AR062357A1/es unknown
- 2007-08-13 TW TW096129866A patent/TW200817362A/zh unknown
- 2007-08-13 PE PE2007001079A patent/PE20080543A1/es not_active Application Discontinuation
-
2009
- 2009-01-19 IL IL196599A patent/IL196599A0/en unknown
-
2010
- 2010-05-10 US US12/776,748 patent/US8026255B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR101117931B1 (ko) | 2012-04-12 |
| CA2658960A1 (en) | 2008-02-21 |
| AU2007286344A1 (en) | 2008-02-21 |
| CN101506165A (zh) | 2009-08-12 |
| JP2010500391A (ja) | 2010-01-07 |
| WO2008019967A2 (en) | 2008-02-21 |
| US8026255B2 (en) | 2011-09-27 |
| TW200817362A (en) | 2008-04-16 |
| BRPI0715967A2 (pt) | 2013-08-06 |
| EP2054385A2 (en) | 2009-05-06 |
| US20080045544A1 (en) | 2008-02-21 |
| CL2007002347A1 (es) | 2008-03-14 |
| KR20090031620A (ko) | 2009-03-26 |
| MX2009001498A (es) | 2009-02-18 |
| IL196599A0 (en) | 2009-11-18 |
| CN101506165B (zh) | 2012-07-04 |
| US7754744B2 (en) | 2010-07-13 |
| PE20080543A1 (es) | 2008-05-16 |
| US20100222350A1 (en) | 2010-09-02 |
| WO2008019967A3 (en) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062357A1 (es) | Derivados de fenilo, piridina y quinolina, composiciones farmaceuticas y su utilizacion como medicamentos | |
| ES2564179T3 (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR044401A1 (es) | Compuestos derivados de quinoleina, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos. | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| DOP2001000270A (es) | Agonistas del receptor 3-adrenergico y usos de los mismos | |
| CR10614A (es) | Derivados heterociclicos fusionados y metodos de uso | |
| PE20040909A1 (es) | Derivados fluoroglicosidos aromaticos con afinidad por el receptor sglt2 | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| CU20090132A7 (es) | Compuestos tricíclicos, composiciones y procedimientos | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| PE20070431A1 (es) | Compuestos y composiciones de carboxamidas sustituidas como moduladores de receptores cannabinoides | |
| UY33961A (es) | Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona | |
| UY30804A1 (es) | Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones | |
| UY31545A1 (es) | Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones | |
| UY30938A1 (es) | Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones. | |
| AR059886A1 (es) | Derivados de amidas como inhibidores de renina | |
| AR052588A1 (es) | Derivados de benzotiazol tiazolopiridina benzooxazol y oxazolopiridina | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |